In patients with EGFRm NSCLC and LM, osimertinib shows superior efficacy compared to first- and second-generation EGFR-TKIs, significantly improving PFS and OS (30, 31), regardless of the presence of T790M mutations in the CSF. Here, EGFR is linked to non-small cell lung carcinoma.